Company profile: Crescendo Biologics
1.1 - Company Overview
Company description
- Provider of Humabody VH-based antibody therapeutics and a discovery platform enabling rapid discovery of fully human VH domains for small, stable multi-specifics. Offerings include CB307 (PSMA x CD137 bispecific in trial for metastatic castration-resistant prostate cancer), CB213 (preclinical PD-1 x LAG-3), and ZL-1102 (topical IL-17A; licensed to Zai Lab). Also engages in partnered and licensed programs with BioNTech, Takeda.
Products and services
- Humabody VH Platform: Proprietary technology enabling rapid discovery of fully human VH domains to engineer small, stable, easily assembled multi-specific therapeutics for next-generation antibody products
- CB307: Clinical-stage PSMA x CD137 bispecific Humabody architects selective activation of tumor-specific T cells within the tumor microenvironment, targeting metastatic castration-resistant prostate cancer
- Partnered & Licensed Programs: Portfolio-scale collaborations with BioNTech, Takeda, and others deliver discovery, development, and commercialization of Humabody-based therapeutics across various disease areas.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Crescendo Biologics
Argenx
HQ: United States
Website
- Description: Provider of immunology therapies for severe autoimmune diseases and cancer, including efgartigimod, an investigational antibody fragment targeting FcRn for severe autoimmune diseases with pathogenic IgG autoantibodies; ARGX-117, a humanized sweeping antibody inhibiting C2 and downstream complement in IgM-driven diseases; and empasiprubart, a human IgG1 anti-C2 sweeping antibody with enhanced FcRn binding to improve C2 clearance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Argenx company profile →
XNK Therapeutics
HQ: Sweden
Website
- Description: Provider of clinical-stage autologous NK cell–based immunotherapies for cancer, leveraging a proprietary platform for development and manufacture. Pipeline includes evencaleucel in Phase II for multiple myeloma with isatuximab, and preclinical candidates XNK02 (AML), XNK03 (urothelial cancer), and XNK04 (hepatocellular carcinoma). Holds a GMP manufacturing license.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full XNK Therapeutics company profile →
Ab Initio Biotherapeutics
HQ: United States
Website
- Description: Provider of antigen discovery and antibody generation solutions using a proprietary platform targeting multi-transmembrane proteins such as GPCRs, supporting therapeutics for neurological, cardiovascular, endocrine and gastrointestinal disorders; offerings include antibody optimization, single B-cell screening of immune repertoires, the OmniAb Discovery Platform, OmniRat and OmniMouse with high-throughput screening.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ab Initio Biotherapeutics company profile →
Maverick Therapeutics
HQ: United States
Website
- Description: Provider of T cell immunotherapies for solid tumor cancers, developing breakthrough treatments with improved safety and efficacy via COBRA, the most advanced bispecific T cell engaging platform in its class designed to safely target solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Maverick Therapeutics company profile →
Morphotek
HQ: United States
Website
- Description: Provider of gene evolution-based monoclonal antibody products to treat cancer, inflammation, and infectious diseases. Offerings include RESPECT-H+L conjugation technology enabling dual payload delivery with in vivo ADC tracking, and an Eribulin ADC payload with cytotoxic effects on receptor-positive and neighboring receptor-negative tumor cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Morphotek company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Crescendo Biologics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Crescendo Biologics
2.2 - Growth funds investing in similar companies to Crescendo Biologics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Crescendo Biologics
4.2 - Public trading comparable groups for Crescendo Biologics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →